Why the study?
Does enoxaparin compared to unfractionated heparin reduce platelet activity and reactivity in symptomatic patients undergoing carotid endarterectomy?
Does enoxaparin compared to unfractionated heparin reduce platelet activity and reactivity in symptomatic patients undergoing carotid endarterectomy?
Enoxaparin may result in lower formation of platelet-leukocyte aggregates compared to unfractionated heparin during carotid endarterectomy, suggesting a potential benefit in reducing platelet activity.
Favors enoxaparin over UFH to limit platelet-leukocyte aggregates in carotid endarterectomy; extends RCT evidence on LMWH platelet effects.
The aim of this study was to determine platelet activity and reactivity and the effects of unfractionated heparin (UFH) and enoxaparin on platelet function during carotid eversion endarterectomy under local anesthesia. Twenty symptomatic patients undergoing carotid endarterectomy were randomly assigned to either 5,000 units of UFH or body weight-adjusted enoxaparin (0.5 mg/kg body weight) as an intraoperative intravenous bolus. The activity of platelets was assessed by measuring the expression of CD62p and CD41 with flow cytometry. Additionally, platelet-leukocyte aggregates (PLAs) were enumerated. The reactivity of platelets was evaluated by measuring the expression of the same antigens after stimulation. In addition, platelet reactivity was also analyzed using a PFA-100 analyzer. A significant increase in platelet activity was observed during surgery for CD41 and CD62p (p = .002 and < .001, respectively). The number of PLAs showed no significant changes during surgery. Yet there was a significant difference between patients treated with UFH and patients treated with enoxaparin. No difference for platelet activity or reactivity for patients receiving either UFH or enoxaparin prior to cross-clamping of the carotid arteries was seen. The formation of PLAs after endarterectomy was significantly higher in the UFH group; thus, PLAs are probably a useful surrogate parameter for measuring platelet activity.
No takes yet. Share an insight, caveat, or question.
Assadian et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: